Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of apatinib + adebrelimab + etoposide/carboplatin for first-line extensive-stage small cell lung cancer
ChiCTR2500095403Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib and adebrelimab in small cell lung cancer (SCLC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
Rivoceranibadebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500095403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095403.